相关临床试验
19
1 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
2006
进行中（未招募）
1
5.3%
Approved For Marketing
1
5.3%
已完成
16
84.2%
终止
1
5.3%
- ReAlta Life Sciences appointed Jonathan Rigby, a seasoned biotech executive with a track record of raising over $150 million and leading companies through IPOs and strategic exits, to its Board of Directors. - Rigby brings extensive experience from leadership roles at companies including Zogenix (acquired by UCB Pharma for $2 billion) and SteadyMed Therapeutics (acquired by United Therapeutics for $350 million). - The appointment comes as ReAlta advances pegtarazimod, a dual-mechanism peptide targeting neutrophil-driven inflammation and complement activation for treating conditions like Hypoxic Ischemic Encephalopathy in newborns. - Pegtarazimod has received multiple FDA and EMA designations including Orphan Drug and Fast Track status for Hypoxic Ischemic Encephalopathy and acute Graft vs Host Disease.
- Bright Minds Biosciences completed a $175 million public offering to fund clinical trials for its lead epilepsy drug BMB-101, which targets childhood epilepsy through selective serotonin 5-HT2C receptor activation. - The company's BMB-101 compound is designed to avoid the cardiac and psychedelic side effects that plagued previous drugs like fenfluramine by selectively targeting the 2C receptor while avoiding 2A and 2B receptors. - Phase II trial results for BMB-101 in developmental epileptic encephalopathies and absence epilepsy are expected around the end of this year, with the company's stock having appreciated approximately 5,000% over the past 12 months. - Recent acquisitions in the epilepsy space, including Lundbeck's $2.6 billion purchase of Longboard Pharmaceuticals for a similar serotonin 2C mechanism drug, highlight strong industry interest in this therapeutic approach.
- The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration. - Microneedle devices market is expected to reach $2.11 billion in 2024 and grow at a faster CAGR of 6.2%, reflecting technological innovations and applications in personalized medicine. - Key market players include Antares Pharma (acquired by Halozyme), INOVIO Pharmaceuticals, PharmaJet, and 3M, with technological advancements focusing on improved safety, accuracy, and patient compliance.
